We believe off-the-shelf, hypo-immune allogeneic engineered Tregs (EngTregs) that can durably rebalance the immune system are key to commercial success in autoimmune and inflammatory diseases
An off-the-shelf, allogeneic Treg therapy dramatically lowers costs, simplifies manufacturing, and allows faster treatment
The KEY CHALLENGE is to overcome rejection of allogeneic cells by the immune system
OUR SOLUTION
Immune evasive engineering technology shields allogeneic cells from immune rejection to overcome cost, accessibility, and scalability challenges associated with autologous cell therapies
- Knock-out of HLA molecules to block T cell- and antibody-mediated rejection
- A proprietary NK inhibitor that blocks NK-mediated rejection
Provides long-term cell persistence
Readily incorporated into Genti’s current manufacturing process
COGS forecast in the low $1000s per dose allows products to compete directly with biologics